Dbv Technologies ADR (DBVT) Stock Price, Quote & News

Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlie...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 1 55 42 78 78

Website: www.dbv-technologies.com

Address:

BAtiment IRO, 107 Av. de la REpublique, Châtillon, France

Lalalilala Feb. 25 at 8:20 PM

$DBVT This is bad news, coming just two days before a Phase 3 data presentation. Run before it drops to $8 on Monday. 😩

0 · Reply

Lalalilala Feb. 24 at 8:59 PM

$DBVT up . Spéculation thursday expect 26$.

0 · Reply

WolferG Feb. 24 at 12:40 PM

$DBVT Positive Clinical Progress & Regulatory Moves.

0 · Reply

WolferG Feb. 24 at 12:39 PM

$DBVT

0 · Reply

BillionerOfKing Feb. 23 at 8:48 PM

$DBVT Current Stock Price: $21.14

1 · Reply

RodneyHammons200 Feb. 21 at 7:15 AM

$DBVT DBV Technologies develops allergy immunotherapy treatments. Clinical trial outcomes drive valuation. Funding risk remains significant.

0 · Reply

FadeChaser Feb. 18 at 9:17 AM

$DBVT Rare disease biotech where regulatory pathways define upside.

1 · Reply

F_75 Feb. 13 at 2:53 PM

$DBVT read https://finance.yahoo.com/news/dbv-technologies-details-viaskin-peanut-121318017.html and you can find out where the journey with DBVT will go from 2027

0 · Reply

OfficialStocktwitsUser Feb. 12 at 11:32 PM

$DBVT RSI: 40.31, MACD: 0.8535 Vol: 1.39, MA20: 22.30, MA50: 19.72 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BioTechHealthX Feb. 12 at 5:09 PM

$DBVT Long before “exposure management” became a buzzword in tech, DBV Technologies was already chasing “exposure” in immunology—controlled micro-exposures through the skin via the VIASKIN platform. Learn the background behind the epicutaneous immunotherapy story driving DBVT stock interest. https://biotechhealthx.com/biotech-news/dbv-technologies-dbvt-didnt-chase-a-fad-it-built-a-category-the-peanut-allergy-patch/

0 · Reply

DBV Technologies To Present Additional VITESSE Phase 3 Data In Peanut-Allergic Children

2026-02-10T21:34:00.000Z - 15 days ago

DBV Technologies S.A.: DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

2026-02-10T21:30:00.000Z - 15 days ago

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

Tue, 10 Feb 2026 16:30:00 -0500 - 15 days ago

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

2026-02-09T21:34:00.000Z - 16 days ago

DBV Technologies S.A.: DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit

2026-02-05T21:34:00.000Z - 20 days ago

DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

Thu, 05 Feb 2026 16:30:00 -0500 - 20 days ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

2026-01-16T23:22:00.000Z - 5 weeks ago

DBV Technologies S.A.: DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

Fri, 16 Jan 2026 18:11:00 -0500 - 5 weeks ago

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

Mon, 12 Jan 2026 16:00:00 -0500 - 6 weeks ago

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

2026-01-07T21:10:00.000Z - 7 weeks ago

DBV Technologies S.A.: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

2026-01-05T21:11:00.000Z - 7 weeks ago

DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

Mon, 05 Jan 2026 16:00:00 -0500 - 7 weeks ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

2025-12-28T18:06:17.000Z - 2 months ago

The Insider Report: A Tape Fitting for the Holiday

2025-12-17T17:22:20.000Z - 2 months ago

DBV Launches, Up As Much As 46%, On A New Approach To Peanut Allergy

2025-12-17T15:34:22.000Z - 2 months ago

DBVT: HC Wainwright Raises Price Target to $40, Maintains Buy Rating | DBVT Stock News

2025-12-17T15:07:13.000Z - 2 months ago

Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday

Wed, 17 Dec 2025 08:49:57 -0500 - 2 months ago

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

2025-12-17T13:49:57.000Z - 2 months ago

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

2025-12-17T13:34:43.000Z - 2 months ago

DBVT: Analyst Jonathan Wolleben Raises Price Target to $45 | DBVT Stock News

2025-12-17T13:31:25.000Z - 2 months ago

DBVT: Guggenheim Raises Price Target Amid Buy Recommendation | DBVT Stock News

2025-12-17T12:55:28.000Z - 2 months ago

DBVT Surges on Positive Phase 3 Peanut Allergy Patch Trial Results

2025-12-17T11:56:09.000Z - 2 months ago

DBV Technologies surges on Phase 3 trial win for peanut allergy therapy

2025-12-17T11:01:00.000Z - 2 months ago

These Stocks Are Moving the Most Today: Tesla, Netflix, Lennar, DBV Technologies, Micron, and More

2025-12-17T07:27:39.000Z - 2 months ago

DBVT Soars On Positive Phase 3 Trial Of VIASKIN Peanut Patch

2025-12-17T03:10:05.000Z - 2 months ago

DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript

2025-12-16T22:25:28.000Z - 2 months ago

DBVT Stock Surges Over 78% in After-Hours Trading

2025-12-16T21:27:46.000Z - 2 months ago

DBVT's Phase 3 Trial of Viaskin Peanut Patch Yields Promising Results

2025-12-16T21:10:00.000Z - 2 months ago

DBV Technologies S.A.: DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years

2025-12-16T21:05:00.000Z - 2 months ago

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years

2025-12-15T13:13:01.000Z - 2 months ago

This SiTime Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

2025-12-15T12:30:21.000Z - 2 months ago

DBVT Stock: HC Wainwright & Co. Raises Price Target to $35.00 | DBVT Stock News

2025-12-15T12:01:00.000Z - 2 months ago

Cantor Fitzgerald Initiates Coverage on DBVT with Overweight Rating | DBVT Stock News

2025-12-13T00:34:37.000Z - 2 months ago

Janus Henderson Group PLC Acquires Significant Stake in DBV Technologies SA

2025-12-11T06:46:33.000Z - 2 months ago

DBV Technologies: Uncertainty Still Exists Despite Recent 90% Rally

2025-12-03T16:31:36.000Z - 3 months ago

DBVT: Guggenheim Initiates Coverage with 'Buy' Rating and $35 PT | DBVT Stock News

2025-12-02T21:10:00.000Z - 3 months ago

DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025

2025-11-12T11:27:34.000Z - 3 months ago

DBVT Completes Key Phase 3 Trial for Peanut Allergy Treatment

2025-11-12T07:38:44.000Z - 3 months ago

DBV Technologies On Track To Report Data From VITESSE Phase 3 Trial Of VIASKIN Peanut Patch In Q4

2025-11-12T04:50:00.000Z - 3 months ago

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years

Tue, 11 Nov 2025 23:50:00 -0500 - 3 months ago

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

Tue, 04 Nov 2025 16:30:00 -0500 - 4 months ago

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Mon, 03 Nov 2025 16:30:00 -0500 - 4 months ago

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

Thu, 30 Oct 2025 16:30:00 -0400 - 4 months ago

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

2025-10-30T07:00:00.000Z - 4 months ago

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

Thu, 30 Oct 2025 03:00:00 -0400 - 4 months ago

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

Wed, 29 Oct 2025 18:47:00 -0400 - 4 months ago

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

2025-10-29T19:32:25.000Z - 4 months ago

DBVT: HC Wainwright & Co. Raises Price Target, Maintains 'Buy' Rating | DBVT Stock News

2025-10-28T22:12:32.000Z - 4 months ago

DBVT Sees Significant Increase in Cash Reserves in Third Quarter

2025-10-17T13:16:00.000Z - 4 months ago

Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength?

Sep 18, 2025, 4:30 PM EDT - 5 months ago

DBV Technologies Announces Resignation of Board Member

Sep 5, 2025, 4:30 PM EDT - 6 months ago

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

Jul 29, 2025, 4:17 PM EDT - 7 months ago

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

Jul 29, 2025, 4:08 PM EDT - 7 months ago

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

Jul 28, 2025, 4:30 PM EDT - 7 months ago

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Jul 22, 2025, 4:30 PM EDT - 7 months ago

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer

Jun 25, 2025, 4:15 PM EDT - 8 months ago

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

Jun 12, 2025, 4:05 PM EDT - 9 months ago

DBV Technologies to Participate in Upcoming EAACI Congress 2025

Jun 11, 2025, 4:30 PM EDT - 9 months ago

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Jun 3, 2025, 4:30 PM EDT - 9 months ago

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

May 15, 2025, 4:30 PM EDT - 10 months ago

Combined General Meeting of June 11, 2025

May 5, 2025, 4:30 PM EDT - 10 months ago

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

Apr 30, 2025, 4:00 PM EDT - 10 months ago

DBV Technologies Reports First Quarter 2025 Financial Results

Apr 11, 2025, 4:30 PM EDT - 11 months ago

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

Mar 28, 2025, 11:09 AM EDT - 11 months ago

DBV Technologies ADRs Rise After Up to $306.9M in New Financing

Mar 27, 2025, 10:30 PM EDT - 11 months ago

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

Mar 24, 2025, 2:30 AM EDT - 1 year ago

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results

Feb 25, 2025, 4:01 PM EST - 1 year ago

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

Dec 12, 2024, 9:59 AM EST - 1 year ago

DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids

Dec 11, 2024, 4:05 PM EST - 1 year ago

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Nov 11, 2024, 4:30 PM EST - 1 year ago

DBV Technologies Announces Plan to Implement ADS Ratio Change

Nov 6, 2024, 4:30 PM EST - 1 year ago

DBV Technologies Reports Third Quarter 2024 Financial Results

Oct 22, 2024, 4:45 PM EDT - 1 year ago

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

Oct 18, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

Sep 23, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

Sep 4, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Jul 30, 2024, 10:03 PM EDT - 1 year ago

DBV Technologies S.A. (DBVT) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 5:30 PM EDT - 1 year ago

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

Jul 30, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

Jul 29, 2024, 1:30 AM EDT - 1 year ago

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

Jun 5, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 30, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

May 16, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Announces Results of its 2024 Combined General Meeting

May 9, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in Upcoming Investor Conferences

May 7, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

Apr 25, 2024, 4:30 PM EDT - 1 year ago

Combined General Meeting of May 16, 2024

Mar 8, 2024, 9:33 AM EST - 2 years ago

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

Lalalilala Feb. 25 at 8:20 PM

$DBVT This is bad news, coming just two days before a Phase 3 data presentation. Run before it drops to $8 on Monday. 😩

0 · Reply

Lalalilala Feb. 24 at 8:59 PM

$DBVT up . Spéculation thursday expect 26$.

0 · Reply

WolferG Feb. 24 at 12:40 PM

$DBVT Positive Clinical Progress & Regulatory Moves.

0 · Reply

WolferG Feb. 24 at 12:39 PM

$DBVT

0 · Reply

BillionerOfKing Feb. 23 at 8:48 PM

$DBVT Current Stock Price: $21.14

1 · Reply

RodneyHammons200 Feb. 21 at 7:15 AM

$DBVT DBV Technologies develops allergy immunotherapy treatments. Clinical trial outcomes drive valuation. Funding risk remains significant.

0 · Reply

FadeChaser Feb. 18 at 9:17 AM

$DBVT Rare disease biotech where regulatory pathways define upside.

1 · Reply

F_75 Feb. 13 at 2:53 PM

$DBVT read https://finance.yahoo.com/news/dbv-technologies-details-viaskin-peanut-121318017.html and you can find out where the journey with DBVT will go from 2027

0 · Reply

OfficialStocktwitsUser Feb. 12 at 11:32 PM

0 · Reply

BioTechHealthX Feb. 12 at 5:09 PM

0 · Reply

BioTechHealthX Feb. 12 at 8:58 AM

$MBRX $ACHV $AVTX $DBVT $MNMD 2026 is packed with Phase 2 results, Phase 3 topline data, and FDA decision dates that can reprice biotech stocks fast. This watchlist screens NYSE/NASDAQ names under $2B market cap and ranks the top 5 by market cap—built for investors hunting asymmetric upside. https://biotechhealthx.com/biotech-news/top-5-best-biotech-micro-caps-with-major-clinical-catalysts-in-2026/

0 · Reply

OpenOutcrier Feb. 11 at 1:48 PM

$DBVT (-5.7% pre) DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting https://ooc.bz/l/92943

0 · Reply

Elegant_Confusion Feb. 4 at 3:28 PM

$DBVT no that is wrong! DBVT is developing a patch for desensitization to peanut allergies, with successful trials in children age 4 to 7, and impending trials for toddlers age 1 to 4. Several other companies are developing vaccines for peanut allergies using different approahes. For all of them, the regulatory path is indeed challenging, and commercial uptake uncertain, especially with all the vaccine hesitancy we have now.

0 · Reply

RiskAtlas Feb. 4 at 2:06 PM

$DBVT is a biotech developing a vaccine for peanut allergy; its regulatory path has been challenging, and commercial uptake remains uncertain.

0 · Reply

Uujingt Jan. 26 at 11:05 PM

$DBVT https://www.boursier.com/actions/actualites/news/dbv-technologies-adage-capital-management-lp-sur-les-5-des-parts-976865.html

0 · Reply

Love_To_Learn Jan. 26 at 2:00 PM

$DBVT 24.02 me as well all of it ! *

0 · Reply

Love_To_Learn Jan. 26 at 1:53 PM

$DBVT u will b important for me next short while *

0 · Reply

Love_To_Learn Jan. 26 at 1:43 PM

$DBVT been accumulating u up behind the scenes of all the major pops lately and built some insulation and have worked the 25.02 quite extensively

0 · Reply

neangewo Jan. 23 at 12:47 PM

$DBVT So much for the aforementioned warrant exercise sell off.

1 · Reply

Elegant_Confusion Jan. 23 at 11:00 AM

$DBVT BV Technologies (DBVT) plans to submit a Biologics License Application (BLA) in the first half of 2026 for children aged 4–7, based on positive results from the Phase 3 VITESSE trial. A separate and accelerated approval submission for toddlers aged 1–3 is planned for the second half of 2026, widening the market considerably. Hold your bag and collect your reward for your patience! Since the success of P3 trials, exercise of warrants has strengthened the company’s financial position. Some dilution from warrants was always expected, and was already reflected in market prices. Now the path is clear for SP growth! Extremely bullish!

0 · Reply

Social_Idiot Jan. 20 at 9:53 PM

$DBVT Peanut patch excitement. My AI says gap tomorrow.

0 · Reply

MaxWarren Jan. 19 at 7:37 PM

$DBVT Solid biotech profile, tape slow but patient hands absorbing dips

0 · Reply

Market Cap	1.22B
Revenue (ttm)	4.15M
Net Income (ttm)	-113.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,745.06%
Debt to Equity Ratio	0.00

Volume	142,800
Avg Vol	473,822
Day's Range	N/A - N/A
Shares Out	54.97M
Stochastic %K	68%
Beta	-0.98
Analysts	Strong Sell
Price Target	$39.99